Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

← catalyst calendar

NCT06101095

Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.

Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
69actual
Sites
30
Countries
Brazil, Canada, Israel +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-11-29actualWhen the study began enrolling
Primary completion2025-11-05actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-02-01estimatedThe whole study's end, after follow-up
First posted2023-10-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-12-23actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Eosinophilic Oesophagitis

Interventions

  • Drug: Dupilumab
  • Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF
Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)
measured From baseline to Week 24

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed